CTRI/2021/01/030684招募中未知
A RANDOMIZED TRIAL OF MODIFIED VALSALVA VERSUS STANDARD VALSALVA MANEUVER FOR CARDIOVERSION IN PATIENTS WITH SUPRAVENTRICULAR TACHYCARDIA IN EMERGENCY DEPARTMENT
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients/Legally Authorized Representative(LAR) providing Informed consent
- •2. Diagnosis of supraventricular tachycardia (SVT; regular, narrow complex tachycardia with QRS duration <0.12 s on ECG with absent or overt p wave)
排除标准
- •I. Unable or unwilling to give informed consent
- •II. Unstable condition (systolic blood pressure (BP) <90 mm Hg or any indication for immediate drug or direct current cardioversion)
- •III. Atrial fibrillation/atrial flutter/sinus tachycardia/MAT on ECG
- •IV. Systemic hypoperfusion
- •i. Altered mentation
- •ii. Chest pain (due to coronary ischemia)
- •iii. Dyspnea (due to pulmonary edema)
- •V. Severe hypertension (systolic BP >220 mm Hg or diastolic BP >120 mm Hg)
- •VI. Any contraindication to or inability to performing a Valsalva maneuver
- •VII. Contraindication or inability to lay flat and have legs lifted (or any reason identified by the patient as to why this maneuver would cause discomfort or pain)
- •VIII. Pregnancy
- •IX. Myocardial Infarction( <3 months)
- •X. Known case of glaucoma or retinopathy
- •XI. Previous inclusion in the study
研究者
相似试验
已完成
不适用
Modified Valsalva Effectivness in Re-entrant Tachycardias (REVERT) studyRe-entrant TachycardiaCirculatory SystemRe-entry ventricular arrhythmiaISRCTN67937027Royal Devon and Exeter Foundation Trust (UK)372
尚未招募
1 期
Efficacy of Modified Valsalva Maneuver versus Standard Valsalva Maneuver on Clinical Outcomes and Satisfaction of Children Suffering from Paroxysmal Supraventricular TachycardiaCirculatory SystemParaoxsmal supraventricular tachycardiaPACTR202407479098909faculty of nursing of tanta university90
招募中
4 期
Comparison of three methods of pain relief in patients undergoing gall bladder surgeryCTRI/2013/03/003493I150
已完成
不适用
A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIVE ASPERGILLOSIS IN PEDIATRIC SUBJECTS AGED 2 TO 17 YEARS-B44 AspergillosisB44AspergillosisPER-120-10PFIZER S.A.,
进行中（未招募）
不适用
Voriconazole and Anidulafungin in Combination for Aspergillosis in Pediatric SubjectsPrimary therapy of invasive aspergillosis (IA) in pediatric subjects aged 2 to 17 years.MedDRA version: 14.1Level: PTClassification code 10003488Term: AspergillosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-021231-14-Outside-EU/EEAPfizer Inc. 235 East 42nd Street, New York, NY 1001760